Drug Type Small molecule drug |
Synonyms Cicletanine (USAN/INN), cycletanide + [5] |
Mechanism α-adrenergic receptor agonists(Alpha adrenergic receptor agonists), β-adrenoceptors agonists(Beta adrenergic receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 Jan 1988), |
RegulationOrphan Drug (US) |
Molecular FormulaC14H12ClNO2 |
InChIKeyCVKNDPRBJVBDSS-UHFFFAOYSA-N |
CAS Registry89943-82-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03487 | Cicletanine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | JP | 01 Jan 1988 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Arterial Hypertension | Phase 3 | AT | 01 Jan 2009 | |
Pulmonary Arterial Hypertension | Phase 2 | DE | 01 Jan 2009 | |
Pulmonary Arterial Hypertension | Phase 2 | DE | 01 Jan 2009 | |
Pulmonary Arterial Hypertension | Phase 2 | IL | 01 Jan 2009 | |
Pulmonary Arterial Hypertension | Preclinical | GB | 01 Jan 2009 | |
Pulmonary Arterial Hypertension | Preclinical | AT | 01 Jan 2009 | |
Pulmonary Arterial Hypertension | Preclinical | IL | 01 Jan 2009 | |
Pulmonary Arterial Hypertension | Preclinical | BE | 01 Jan 2009 | |
Pulmonary Arterial Hypertension | Discovery | BE | 01 Jan 2009 | |
Pulmonary Arterial Hypertension | Discovery | GB | 01 Jan 2009 |
Phase 2 | 162 | (eotcregzeu) = puqnqdfvnj baiuggnszu (neqzdexyux, -8.0 to 24.0) | Negative | 01 Sep 2012 | |||
(eotcregzeu) = xqtbqezgwp baiuggnszu (neqzdexyux, -8.0 to 24.0) |